INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Inhibrx Biosciences, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$89.79−0.04 (-0.04%)

Close on Oct 19, 2026

Market cap: $1.41B
P/E (TTM): –
Dividend yield: –

Inhibrx Biosciences, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	1.30	0.20	1.80	2.19	7.23	13	13
Research & Development	113	204	192	110	71	73	48
General & Administrative	23	128	29	21	12	6.84	6.26
Operating Expenses	136	332	221	131	84	80	57
Operating Income	-135	-331	-219	-129	-77	-67	-44
Interest Expense	12	13	32	–	–	–	–
Income from Equity Investments	–	0	-1.63	0	0	-0.49	0
Other Non-Operating Income	-5.03	2,019	-21	-16	-5.20	-8.19	-6.79
Gain (Loss) on Sale of Assets	-0.01	-0.01	0.00	-0.02	0.01	0	-0.07
Pretax Income	-140	1,688	-240	-145	-82	-76	-51
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.90
Net Income incl. Noncontrolling Interests	–	–	–	–	-82	-76	-51
Net Income	-140	1,688	-241	-145	-82	-76	-51
EPS (Basic)(per share)	-9.04	114.01	-20.48	-14.48	-8.60	-12.04	-11.32
EPS (Diluted)(per share)	-9.04	112.62	-20.48	-14.48	-8.60	-12.04	-11.32
Shares Outstanding (Basic, Weighted)(shares)	15	15	12	10	9.50	6.32	4.54
Shares Outstanding (Diluted, Weighted)(shares)	15	15	12	10	9.50	6.32	4.54
EBITDA	-133	-329	-218	-128	-75	-66	-43

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -9831.6%
Net margin: -10629.3%
Return on equity, FY2025: -197.8%

Financial strength

Current ratio: 5.07
Debt to equity: -3.33
Debt to assets: 114.3%
Cash to current liabilities: 475.1%

Valuation

P/E ratio: –
Price to sales: 1082.25
Price to book: –
Dividend yield: –